Treatment of acute host-versus-graft reaction in patients after allogeneic hematopoietic cell transplantation with multipotent mesenchymal stromal cells from a bone marrow donor


Cite item

Full Text

Abstract

Aim. To evaluate the efficiency of administration of multipotent mesenchymal stromal cells obtained from a bone marrow donor for the treatment of an acute host-versus-graft reaction (HVGR) resistant to therapy with glucocorticosteroids (GCS). Subjects and methods. The experience in treating 6 patients with GCS-resistant acute HVGR following allogeneic hematopoietic stem cell transplantation is given. The patients were intravenously injected cultured multipotent mesenchymal stromal cells (MMSC) in a dose of 106 per kg body weight. Results. Four weeks after MMSC administration, a complete or partial response was obtained in 3 cases; clinical improvement was noted in 2; one patient showed no response. MMSC therapy proved to be effective in 5 of the 6 cases with acute HVGR resistant to GCS therapy. Conclusion. MMSC therapy turned out to be effective in case of acute HVGR resistant to GCS therapy.

Full Text

Лечение острой реакции "трансплантат против хозяина" у больных после трансплантации аллогенных гемопоэтических клеток мультипотентными мезенхимальными стромальными клетками из костного мозга донора. - Резюме. Цель исследования. Оценка эффективности введения мультипотентных мезенхимальных стромальных клеток, полученных из костного мозга донора, для лечения острой реакции "трансплантат против хозяина" (РТПХ), резистентной к терапии глюкокортикостероидами (ГКС). Материалы и методы. Представлен опыт лечения 6 больных с резистентной к ГКС острой РТПХ после трансплантации аллогенных гемопоэтических стволовых клеток. Больным вводили внутривенно культивированные мультипотентные мезенхимальные стромальные клетки (ММСК) в дозе 106 на 1 кг массы тела. Результаты. Через 4 нед после введения ММСК в 3 случаях получен полный или частичный ответ, в 2 отмечено клиническое улучшение, у одного пациента ответ не получен. Терапия ММСК оказалась эффективной в 5 случаях из 6 при возникновении острой РТПХ, резистентной к терапии ГКС. Заключение. Терапия ММСК оказалась эффективной при возникновении острой РТПХ, резистентной к лечению ГКС.
×

References

  1. Mohty M., Apperley J.F. Long-term physiological side effects after allogeneic bone marrow transplantation. Hematology Am Soc Hematol Educ Program 2010; 2010: 229-236.
  2. Majumdar M.K., Keane-Moore M. et al. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci 2003; 10: 228-241.
  3. Svinareva D.A., Shipunova I.N., Ol'shanskaia I. et al. The basic properties of mesenchymal stromal cells from the donor bone marrow: superficial markers. Ter Arkh 2010; 82: 52-56.
  4. Jones B.J., McTaggart S.J. Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp Hematol 2008; 36: 733-741.
  5. Djouad F., Charbonnier L.M., Bouffi C. et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 2007; 25: 2025-2032.
  6. Jiang X.X., Zhang Y., Liu B. et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105: 4120-4126.
  7. Ramasamy R., Fazekasova H., Lam E.W. et al. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 2007; 83: 71-76.
  8. Zhang W., Ge W., Li C. et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 2004; 13: 263-271.
  9. Krampera M., Glennie S., Dyson J. et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101: 3722-3729.
  10. Le Blanc K., Rasmusson I., Gotherstrom C. et al. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol 2004; 60: 307-315.
  11. Glennie S., Soeiro I., Dyson P.J. et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005; 105: 2821-2827.
  12. Plumas J., Chaperot L., Richard M.J. et al. Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 2005; 19: 1597-1604.
  13. Corcione A., Benvenuto F., Ferretti E. et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107: 367-372.
  14. Deng W., Han Q., Liao L. et al. Effects of allogeneic bone marrow-derived mesenchymal stem cells on T and B lymphocytes from BXSB mice. DNA Cell Biol 2005; 24: 458-463.
  15. Le Blanc K., Rasmusson I., Sundberg B. et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439-1441.
  16. Muller I., Kordowich S., Holzwarth C. et al. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis 2008; 40: 25-32.
  17. Fang D., Seo B.M., Liu Y. et al. Transplantation of mesenchymal stem cells is an optimal approach for plastic surgery. Stem Cells 2007; 25: 1021-1028.
  18. Ringden O., Uzunel M., Rasmusson I. et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81: 1390-1397.
  19. Lazarus H.M., Koc O.N., Devine S.M. et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11: 389-398.
  20. Ringden O., Uzunel M., Rasmusson I. et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81: 1390-1397.
  21. Jones B.J., McTaggart S.J. Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp Hematol 2008; 36: 733-741.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies